Evox Therapeutics

OverviewSuggest Edit

Evox Therapeutics is a biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop a new class of therapeutics. The Company creates substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system.
TypePrivate
Founded2016
HQOxford, GB
Websiteevoxtherapeutics.com

Latest Updates

Employees (est.) (Jun 2021)121(+3%)
Cybersecurity ratingAMore

Key People/Management at Evox Therapeutics

Antonin de Fougerolles

Antonin de Fougerolles

Chief Executive Officer and Director
Paul Carter

Paul Carter

Non-Executive Chairman
Simon Dew

Simon Dew

VP, Business Development
Sarah Gordon Wild

Sarah Gordon Wild

Non-Executive Director
Bo Kara

Bo Kara

VP, Process Development
Kerry Jaycock

Kerry Jaycock

HR Director
Show more

Evox Therapeutics Office Locations

Evox Therapeutics has offices in Oxford and Solna
Oxford, GB (HQ)
Magdalen Centre, Robert Robinson Ave
Solna, SE
Karolinska Institutet Science Park, Hälsovägen 7
Show all (2)

Evox Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Evox Therapeutics total Funding

$158.6 m

Evox Therapeutics latest funding size

$95.98 m

Time since last funding

4 months ago

Evox Therapeutics investors

Evox Therapeutics's latest funding round in February 2021 was reported to be $96 m. In total, Evox Therapeutics has raised $158.6 m
Show all financial metrics

Evox Therapeutics Revenue

Cash (31-Dec-2018)

36.3m
GBPFY, 2016FY, 2017FY, 2018

Cash

8.9m5.3m36.3m

Accounts Receivable

151.0k350.0k

Current Assets

9.1m6.5m38.0m
FY, 2016

Financial Leverage

1 x
Show all financial metrics

Evox Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Evox Therapeutics Online and Social Media Presence

Embed Graph

Evox Therapeutics News and Updates

Evox Therapeutics completes £69.2 million Series C financing

OXFORD, England, Feb. 18, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round. The financing was significantly oversubscribed with high...

John McHutchison joins the Board of Evox Therapeutics

OXFORD, England, Jan. 18, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ("Evox" or the "Company"), a leading exosome therapeutics company, today announces that John McHutchison has joined its Board of Directors. John will be joining the Board as the representative for Oxford Sciences...

Evox Therapeutics expands its existing exosome patent portfolio

OXFORD, England, Nov. 24, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO). This new grant reinforces the Company's...

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

OXFORD, England, Nov. 17, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the launch of a collaboration focused on rare diseases with the University of Oxford's Oxford-Harrington Rare Disease Centre...

Evox Therapeutics appoints Dr David Lowe as Vice President of Research

OXFORD, England, Oct. 13, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr David Lowe as Vice President (VP) of Research. David will be overseeing the 40-person Research group with a...

Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics

OXFORD, England, July 15, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent...
Show more

Evox Therapeutics Blogs

Evox Therapeutics granted key exosome patents covering RNA therapeutics and targeted drug delivery

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that the Company has been granted three key patents by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO). These three new grants are from one of se…

Evox Therapeutics Frequently Asked Questions

  • When was Evox Therapeutics founded?

    Evox Therapeutics was founded in 2016.

  • Who are Evox Therapeutics key executives?

    Evox Therapeutics's key executives are Antonin de Fougerolles, Paul Carter and Simon Dew.

  • How many employees does Evox Therapeutics have?

    Evox Therapeutics has 121 employees.

  • Who are Evox Therapeutics competitors?

    Competitors of Evox Therapeutics include Protalex, Biocept and Exosome Diagnostics.

  • Where is Evox Therapeutics headquarters?

    Evox Therapeutics headquarters is located at Magdalen Centre, Robert Robinson Ave, Oxford.

  • Where are Evox Therapeutics offices?

    Evox Therapeutics has offices in Oxford and Solna.

  • How many offices does Evox Therapeutics have?

    Evox Therapeutics has 2 offices.